Figure 10.

(a) T1w MR images of Vx 2 tumor obtained at baseline and 3 hours after α_vβ₃-Gd-DOTA NP in animals receiving α_vβ₃-no drug NP showing peripheral tumor angiogenesis contrast enhancement false colored in yellow. (b) The same image sequence as panel (a) in Vx2 tumor rabbits following α_vβ₃-Dxtl-PD NP. (c) Histogram illustrating marked angiogenesis in the control rabbits rim (tumor peripheral 50%) versus those receiving Dtxl-PD with or without targeting. Note minimal contrast signal with the tumor core. Marked decrease in contrast in nontargeted (NT) animal group suggests that the dosage or frequency of treatment was in excess of the therapeutic need with passive entrapment providing adequate particle-to-endothelium contact to afford significant antiangiogenesis. (d) Representative three-dimensional neovascular maps of Vx2 tumor in control and targeted Dxtl-PD treatment groups. Note asymmetric distribution of confluent neovascular regions in the control rabbit note appreciated in the treated animal. Blue voxels equate to α_vβ₃-Gd-DOTA NP contrast enhancement exceeding three standard deviations over baseline. ^*P < 0.05, ^**P < 0.01. (Reprinted with permission from Ref 74. Copyright 2014)